Lars Hytting
investorMale0.0Global Dominance: 0.00%
Lars Hytting is an investor at ArthaScope, known for his insights into the pharmaceutical market. Recently, he commented on the unexpected drop in Novo Nordisk's share price, indicating that even the most skeptical analysts did not anticipate such a significant decline, highlighting the intense competition in the weight-loss drug sector.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Investor ArthaScope’s Lars Hytting told Bloomberg that even the most sceptical analyst didn’t anticipate this big a drop.
Ozempic maker Novo Nordisk faces heavy competition from Mounjaro and other weight loss drugs in AustraliaThe Sydney Morning Herald·
Australia· 2026-02-04
Australia· 2026-02-04
